A new study on ecnoglutide, a GLP-1 analogue, was published on September 1, 2026. The publication, titled "Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants," appeared in the journal Diabetes, Obesity & Metabolism.
The study investigated how ecnoglutide affects the pharmacokinetics of rosuvastatin and digoxin when administered to healthy participants. Ecnoglutide remains classified as an unapproved compound under research investigation.
This publication is indexed in PubMed under the identifier 42310888. The event record provided does not include specific findings, results, or conclusions from the study beyond its stated title and focus.
Readers interested in interaction studies involving GLP-1 analogues and commonly used medications such as statins and cardiac glycosides may find this publication relevant to ongoing research in this area. As with all research publications, the full study should be consulted directly for detailed methodology, data, and conclusions.
For more background on this compound, readers can refer to the ecnoglutide overview page.